Highly Placed Media Racists
By Steve Rendall,
FAIR
| 07. 02. 2014
Untitled Document
Nicholas Wade was a leading New York Times science writer for three decades. He left the paper weeks after the May publication of his book, A Troublesome Inheritance: Genes, Race and Human History, a book many reviewers say is a full-throated defense of "scientific racism." Wade's views raise questions about his tenure at the Times, and about corporate media vigilance on coverage of racism.
There are many reasons media fail to adequately challenge racism, particularly racism in high places (FAIR Blog, 6/27/14). But one rarely discussed reason is that some highly placed corporate media figures are open to racism. I documented this a while back in Extra! (4/05), after New York Times columnists David Brooks (12/7/04) and John Tierney (10/24/04) approvingly cited the work of Steve Sailer, a central figure in the promotion of racist and anti-immigrant theories.
For his part, Brooks praised a Sailer article in the American Conservative (12/20/04) promoting a movement that saw white people, as Brooks would have it, flouting Western trends toward...
Related Articles
By Neel Shah, The PrePrint | 04.11.2024
Years ago, I interviewed for a residency position at The Johns Hopkins Hospital in Baltimore. Standing before the domed Victorian building at the campus entrance, I couldn’t help but be in awe of the history of the place, the great...
By Rob Stein, NPR | 03.07.2024
A big federal research project aimed at reducing racial disparities in genetic research has unveiled the program's first major trove of results.
"This is a huge deal," says Dr. Joshua Denny, who runs the All of Us program at...
By Max Kozlov, Nature | 02.23.2024
Some geneticists have expressed their unease about a figure in a high-profile Nature paper that was published earlier this week1, noting that it could be misinterpreted as reinforcing racist beliefs. The figure has reignited a long-standing debate among...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...